Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
ACADIA Pharmaceuticals Inc.
180 participants
Aug 6, 2025
INTERVENTIONAL
Conditions
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Provided as 1 capsule, to be taken orally once daily
Provided as 1 capsule, to be taken orally once daily
Locations(56)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029581